Is LRMR or RANI more profitable?

Larimar Therapeutics' return on equity of -134.14% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% Rani Therapeutics N/A -206.46% -83.95%

Does the media favor LRMR or RANI?

In the previous week, Rani Therapeutics had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Rani Therapeutics and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.73 beat Rani Therapeutics' score of 0.84 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rani Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CCCC or RANI?

In the previous week, Rani Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 4 mentions for Rani Therapeutics and 3 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.87 beat Rani Therapeutics' score of 0.84 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RANI or TENX more profitable?

Tenax Therapeutics' return on equity of -63.18% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Tenax Therapeutics N/A -63.18% -58.93%

Does the media refer more to RANI or TENX?

In the previous week, Tenax Therapeutics had 11 more articles in the media than Rani Therapeutics. MarketBeat recorded 15 mentions for Tenax Therapeutics and 4 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.84 beat Tenax Therapeutics' score of 0.76 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is EOLS or RANI more profitable?

Rani Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evolus -14.39% N/A -19.03% Rani Therapeutics N/A -206.46% -83.95%

Does the media prefer EOLS or RANI?

In the previous week, Evolus had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 6 mentions for Evolus and 4 mentions for Rani Therapeutics. Evolus' average media sentiment score of 1.02 beat Rani Therapeutics' score of 0.84 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AVIR or RANI?

Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 928.20%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Is AVIR or RANI more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% Rani Therapeutics N/A -206.46% -83.95%

Does the media prefer AVIR or RANI?

In the previous week, Atea Pharmaceuticals had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 4 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.84 beat Atea Pharmaceuticals' score of 0.12 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Rani Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rani Therapeutics (RANI) Competitors

$0.85 +0.05 (+6.20%)

As of 02:34 PM Eastern

Compare

RANI vs. LRMR, CCCC, TENX, EOLS, and AVIR

Should you buy Rani Therapeutics stock or one of its competitors? MarketBeat compares Rani Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rani Therapeutics include Larimar Therapeutics (LRMR), C4 Therapeutics (CCCC), Tenax Therapeutics (TENX), Evolus (EOLS), and Atea Pharmaceuticals (AVIR).

How does Rani Therapeutics compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Larimar Therapeutics' return on equity of -134.14% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Rani Therapeutics	N/A	-206.46%	-83.95%

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Larimar Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

In the previous week, Rani Therapeutics had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Rani Therapeutics and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.73 beat Rani Therapeutics' score of 0.84 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rani Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rani Therapeutics has higher revenue and earnings than Larimar Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Rani Therapeutics	$1.63M	64.68	-$29.67M	-$0.41	N/A

Larimar Therapeutics currently has a consensus target price of $12.71, suggesting a potential upside of 211.24%. Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 928.20%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Larimar Therapeutics beats Rani Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rani Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. C4 Therapeutics' return on equity of -50.68% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Rani Therapeutics	N/A	-206.46%	-83.95%

C4 Therapeutics has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

In the previous week, Rani Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 4 mentions for Rani Therapeutics and 3 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.87 beat Rani Therapeutics' score of 0.84 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

C4 Therapeutics presently has a consensus price target of $7.75, suggesting a potential upside of 115.58%. Rani Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 928.20%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Rani Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	11.06	-$104.99M	-$1.19	N/A
Rani Therapeutics	$1.63M	64.68	-$29.67M	-$0.41	N/A

Summary

Rani Therapeutics beats C4 Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Rani Therapeutics compare to Tenax Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Rani Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Rani Therapeutics has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	64.68	-$29.67M	-$0.41	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Rani Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 928.20%. Tenax Therapeutics has a consensus target price of $37.67, suggesting a potential upside of 174.26%. Given Rani Therapeutics' higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Tenax Therapeutics' return on equity of -63.18% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Tenax Therapeutics	N/A	-63.18%	-58.93%

In the previous week, Tenax Therapeutics had 11 more articles in the media than Rani Therapeutics. MarketBeat recorded 15 mentions for Tenax Therapeutics and 4 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.84 beat Tenax Therapeutics' score of 0.76 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenax Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rani Therapeutics beats Tenax Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Evolus?

Evolus (NASDAQ:EOLS) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

In the previous week, Evolus had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 6 mentions for Evolus and 4 mentions for Rani Therapeutics. Evolus' average media sentiment score of 1.02 beat Rani Therapeutics' score of 0.84 indicating that Evolus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evolus presently has a consensus target price of $16.00, indicating a potential upside of 164.46%. Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 928.20%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Rani Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Rani Therapeutics	N/A	-206.46%	-83.95%

90.7% of Evolus shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Evolus has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Rani Therapeutics has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.34	-$51.64M	-$0.67	N/A
Rani Therapeutics	$1.63M	64.68	-$29.67M	-$0.41	N/A

Summary

Rani Therapeutics beats Evolus on 8 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Atea Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 928.20%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Atea Pharmaceuticals had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 4 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.84 beat Atea Pharmaceuticals' score of 0.12 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rani Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rani Therapeutics has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Rani Therapeutics	$1.63M	64.68	-$29.67M	-$0.41	N/A

Atea Pharmaceuticals' return on equity of -57.01% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Rani Therapeutics	N/A	-206.46%	-83.95%

Summary

Rani Therapeutics beats Atea Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Rani Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RANI vs. The Competition

Export

Metric	Rani Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$105.42M	$3.54B	$6.80B	$13.01B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-2.08	7.36	279.98	25.51
Price / Sales	64.68	1,272.68	649.35	116.02
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	2.50	17.18	11.15	6.35
Net Income	-$29.67M	-$12.52M	$3.48B	$347.60M
7 Day Performance	3.87%	2.48%	2.51%	3.14%
1 Month Performance	10.33%	-5.41%	-2.78%	-2.08%
1 Year Performance	55.29%	51.14%	64.32%	21.27%

Rani Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RANI Rani Therapeutics	3.3042 of 5 stars	$0.85 +6.2%	$8.75 +928.2%	+51.6%	$105.42M	$1.63M	N/A	110	Upcoming Earnings
LRMR Larimar Therapeutics	4.4707 of 5 stars	$3.76 -2.0%	$12.71 +238.6%	+15.7%	$390.08M	N/A	N/A	30	Positive News Earnings Report
CCCC C4 Therapeutics	2.2803 of 5 stars	$3.50 -4.5%	$7.75 +121.7%	+65.1%	$385.33M	$34.86M	N/A	150	Positive News Upcoming Earnings
TENX Tenax Therapeutics	3.1652 of 5 stars	$14.52 -3.9%	$37.67 +159.5%	+130.4%	$385.10M	N/A	N/A	9	Earnings Report
EOLS Evolus	2.641 of 5 stars	$5.77 -4.1%	$16.00 +177.5%	-33.9%	$379.68M	$297.18M	N/A	170	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RANI) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rani Therapeutics (RANI) Competitors

RANI vs. LRMR, CCCC, TENX, EOLS, and AVIR

How does Rani Therapeutics compare to Larimar Therapeutics?

Summary

How does Rani Therapeutics compare to C4 Therapeutics?

Summary

How does Rani Therapeutics compare to Tenax Therapeutics?

Summary

How does Rani Therapeutics compare to Evolus?

Summary

How does Rani Therapeutics compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rani Therapeutics (RANI) Competitors

RANI vs. LRMR, CCCC, TENX, EOLS, and AVIR

How does Rani Therapeutics compare to Larimar Therapeutics?

Is LRMR or RANI more profitable?

Do insiders & institutionals hold more shares of LRMR or RANI?

Which has more volatility & risk, LRMR or RANI?

Does the media favor LRMR or RANI?

Which has preferable valuation and earnings, LRMR or RANI?

Do analysts rate LRMR or RANI?

Summary

How does Rani Therapeutics compare to C4 Therapeutics?

Do insiders and institutionals have more ownership in CCCC or RANI?

Is CCCC or RANI more profitable?

Which has more volatility and risk, CCCC or RANI?

Does the media favor CCCC or RANI?

Do analysts rate CCCC or RANI?

Which has better valuation and earnings, CCCC or RANI?

Summary

How does Rani Therapeutics compare to Tenax Therapeutics?

Which has more volatility & risk, RANI or TENX?

Do institutionals & insiders have more ownership in RANI or TENX?

Which has higher valuation & earnings, RANI or TENX?

Do analysts prefer RANI or TENX?

Is RANI or TENX more profitable?

Does the media refer more to RANI or TENX?

Summary

How does Rani Therapeutics compare to Evolus?

Does the media prefer EOLS or RANI?

Do analysts rate EOLS or RANI?

Is EOLS or RANI more profitable?

Do insiders and institutionals believe in EOLS or RANI?

Which has more volatility and risk, EOLS or RANI?

Which has preferable earnings & valuation, EOLS or RANI?

Summary

How does Rani Therapeutics compare to Atea Pharmaceuticals?

Which has more risk & volatility, AVIR or RANI?

Do analysts prefer AVIR or RANI?

Do institutionals and insiders believe in AVIR or RANI?

Does the media prefer AVIR or RANI?

Which has stronger earnings & valuation, AVIR or RANI?

Is AVIR or RANI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools